Novo Nordisk : SELECT: results that justify a change in patient care
>Confirmation of Wegovy's role in cardiac protection for obese patients - At the AHA (American Heart Association) congress, Novo Nordisk recapped on the clinical results of its SELECT trial. Note that the objective of this trial was to demonstrate that, in patients suffering from obesity and cardiovascular disease without a history of diabetes, taking Wegovy improved cardiovascular function in this population (n=17,604). The primary endpoint was a composite (taking se...Novo-Nordisk is a global healthcare company engaged in the innovation of diabetes care. Co. also provides haemophilia care, growth hormone therapy and hormone replacement therapy. The Diabetes care business segment includes research, development, manufacturing and marketing of products within the areas of insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD) and obesity. The Biopharmaceuticals business segment includes research, development, manufacturing and marketing of products within the areas of haemophilia, growth hormone therapy, hormone replacement therapy, inflammation therapy and other therapy areas.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.